<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04263415</url>
  </required_header>
  <id_info>
    <org_study_id>sema in PCOS</org_study_id>
    <nct_id>NCT04263415</nct_id>
  </id_info>
  <brief_title>The Effects of Semaglutide on Taste, Tongue Tissue Transcriptome, Gastric Emptying and Central Neural Response in Women With PCOS and Obesity</brief_title>
  <official_title>The Effects of Semaglutide on Modulation of Taste Sensitivity, Tongue Tissue Transcriptome, Gastric Emptying and Central Neural Responses in Women With PCOS and Obesity: a Randomized, Single-blind, Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to explore the effects of GLP-1 receptor agonist (GLP-1 RA)
      semaglutide on modulation of taste sensitivity, tongue tissue transcriptome, modulation of
      neural response in central reward processing regions and gastric emptying rate. In addition,
      we aim to investigate the associations between semaglutide induced modulation of taste
      sensitivity, neural responses and gastric emptying with changes in body mass, eating-
      behavioural pattern, food perception and food intake.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2019</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>a randomized, single-blind, placebo-controlled clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The impact of sema on taste and tongue transcriptome</measure>
    <time_frame>Changes in taste senzations using Taste-Streeps and tongue transcriptome using RNA-seq from baseline up to the end of 12th week.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The impact of sema on gastric emptying.</measure>
    <time_frame>Change in gastric emptying from baseline up to the end of 12th week.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The impact of sema on neural response in central reward processing regions</measure>
    <time_frame>fMRI change in neural response from baseline to the end of 12th week of therapy.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>PCOS</condition>
  <condition>Semaglutide</condition>
  <condition>Taste, Altered</condition>
  <condition>Tongue Tissue Transcriptome</condition>
  <condition>Gastric Emptying</condition>
  <condition>Central Neural Response</condition>
  <arm_group>
    <arm_group_label>group P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>once-weekly injection with placebo pen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group S</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once-weekly application of semaglutide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide</intervention_name>
    <description>semaglutide 1mg/week sc for 12 weeks</description>
    <arm_group_label>group S</arm_group_label>
    <other_name>Ozempic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>once-weekly injection with placebo pen for 12 weeks</description>
    <arm_group_label>group P</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed written consent

          -  Diagnosed with PCOS by Rotterdam criteria

          -  BMI &gt; 30 kg/m2

          -  Age 18 years-menopause

        Exclusion Criteria:

          -  Severe psychiatric disease including schizophrenia, paranoid psychosis, bipolar
             disorder or mental retardation

          -  Current history of neurological disease including traumatic brain surgery

          -  Current history of diagnosis of type I or type II diabetes or plasma haemoglobin A1c
             6.5% at inclusion

          -  Impaired hepatic function (liver transaminases&gt;3 times upper normal limit)

          -  Impaired renal function (estimated glomerular filtration rate (eGFR)&lt; 50 ml/min

          -  Impaired pancreatic function (any history of acute or chronic pancreatitis and/or
             amylase &gt;2 times upper limit)

          -  Bleeding disorders

          -  Women who are pregnant, breast feeding or have intention of becoming pregnant within
             the next 9 months

          -  Women who are planning any operation within the next 6 months

          -  History of medullary thyroid carcinoma (MTC) and/or family history with MTC and/or
             multiple endocrine neoplasia syndrome type 2

          -  Cardiac problems defined as decompensated heart failure (New York Herat Association
             functional class III or IV), unstable angina pectoris, and/or myocardial infarction
             within the last 12 months

          -  Uncontrolled hypertension (systolic blood pressure &gt; 180 mmHg, diastolic blood
             pressure &gt; 110 mmHg

          -  Receiving GLP-1 agonist within the last 12 months

          -  Use of any weight-lowering pharmacotherapy within the preceding 3 months

          -  Contraindication for MR scanning (magnetic implants, pacemaker, claustrophobia etc)

          -  Any condition that the investigator feels would interfere with trial participation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrej Jane≈æ, MD PhD</last_name>
    <phone>15223564</phone>
    <phone_ext>+386</phone_ext>
    <email>andrej.janez@kclj.si</email>
  </overall_contact>
  <location>
    <facility>
      <name>UMC Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrej Janez, MD PhD</last_name>
      <phone>15223564</phone>
      <phone_ext>+386</phone_ext>
      <email>andrej.janez@kclj.si</email>
    </contact>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 5, 2020</study_first_submitted>
  <study_first_submitted_qc>February 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2020</study_first_posted>
  <last_update_submitted>February 7, 2020</last_update_submitted>
  <last_update_submitted_qc>February 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>Andrej Janez</investigator_full_name>
    <investigator_title>Clinical professor, Head of the Department of Endocrinology, Diabetes and Metabolic Diseases</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysgeusia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

